Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia
- 31 July 2005
- journal article
- research article
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 52 (3), 187-193
- https://doi.org/10.1016/j.diagmicrobio.2005.05.004
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- In vitro activity of tigecycline against ampicillin-resistant Haemophilus influenzae isolatesJournal of Antimicrobial Chemotherapy, 2005
- In vitro evaluation of tigecycline and comparative agents in 3049 clinical isolates: 2001 to 2002Diagnostic Microbiology and Infectious Disease, 2005
- Tigecycline: a first in class glycylcyclineClinical Microbiology Newsletter, 2004
- In vitro activity of tigecycline (GAR-936) tested against 11,859 recent clinical isolates associated with community-acquired respiratory tract and gram-positive cutaneous infectionsDiagnostic Microbiology and Infectious Disease, 2004
- Activities of Tigecycline (GAR-936) against Legionella pneumophila In Vitro and in Guinea Pigs with L. pneumophila PneumoniaAntimicrobial Agents and Chemotherapy, 2003
- Comparative in vitro activities of tigecycline (GAR-936) and other antimicrobial agents against Stenotrophomonas maltophilia.Journal of Antimicrobial Chemotherapy, 2002
- Antimicrobial resistance among isolates cultured from patients hospitalized with lower respiratory tract infection in EuropeInternational Journal of Infectious Diseases, 2002
- In vitro antimicrobial activity of GAR-936 tested against antibiotic-resistant gram-positive blood stream infection isolates and strains producing extended-spectrum β-lactamasesDiagnostic Microbiology and Infectious Disease, 2001
- Frequency of Isolation of Pathogens from Bloodstream, Nosocomial Pneumonia, Skin and Soft Tissue, and Urinary Tract Infections Occurring in European PatientsEuropean Journal of Clinical Microbiology & Infectious Diseases, 2001
- In-vitro susceptibility of anaerobic bacteria to gar-936, a new glycylcyclineClinical Microbiology & Infection, 2000